Interacting Drugs |
Hyoscyamine, atropine, scopolamine, and phenobarbital vs Lapatinib |
Security Level |
 |
Mechanism |
Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib. |
Management |
If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated. |
Hyoscyamine, atropine, scopolamine, and phenobarbital vs Lapatinib
Post Review about Hyoscyamine, atropine, scopolamine, and phenobarbital vs Lapatinib Click here to cancel reply.
Other Interactions of Hyoscyamine, atropine, scopolamine, and phenobarbital
Other Interactions of Lapatinib
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.